- Subjects must have active rheumatoid arthritis
- Subjects must have failed at least 1 disease modifying anti-rheumatic drug (DMARD)
- Subjects must not be currently taking any DMARD other than an antimalarial
- Subjects who discontinued any previous TNF inhibitor therapy for either lack of
benefit or safety.
- Subjects who previously received adalimumab (Humira®) therapy for any reason.
- Subjects with evidence of blood disorders, chronic infections or untreated